A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging, Efficacy and Safety Study of Three Doses of TCH346 (1mg, 5mg and 20mg Daily) in Patients With Early Parkinson's Disease

This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents

This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents

Inclusion Criteria:

• Male or female ,aged 30-80 years
• Clinical diagnosis of early stage idiopathic Parkinson's disease
• Experiencing two of the three following signs; bradykinesia, rigidity, and tremor
• Not currently taking any antiparkinson medication

Exclusion Criteria:

• A history of alcohol or drug abuse in the past year
• A diagnosis psychiatric illness
• Patients who currently are taking MAO inhibitors within 30 days of entering the study
• Patients who are hypersensitive to selegiline, MAO-B inhibitors, or tricyclic antidepressants

Additional inclusion/exclusion criteria may apply